Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Parkinson's Disease Psychosis
Interventions
Pimavanserin tartrate (ACP-103)
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
40 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
26
States / cities
La Habra, California • Laguna Hills, California • Reseda, California + 22 more
Conditions
Parkinson Disease Psychosis
Interventions
SEP-363856, Placebo capsule
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
55 Years to 105 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
24
States / cities
Fresno, California • Los Angeles, California • Riverside, California + 19 more
Conditions
Healthy Subjects, Schizophrenia, Parkinson Disease
Interventions
Oxygen-15 Water
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 90 Years
Enrollment
1,039 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1993
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Parkinson Disease, Parkinson Disease Psychosis, Hallucinations, Delusion
Interventions
Observation of minor phenomena
Other
Lead sponsor
University of Rochester
Other
Eligibility
30 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Rochester, New York
Conditions
Parkinson's Disease Psychosis
Interventions
pimavanserin tartrate, placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
40 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
62
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 58 more
Completed No phase listed Observational Accepts healthy volunteers

In Vivo Imaging of Therapeutic Electric Current Flow

NCT02453763
Conditions
Parkinson Disease, Epilepsy, Alzheimer's Disease, Stroke, Autism, Depression, Schizophrenia
Interventions
Transcranial direct current stimulation, MRI
Device · Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 30 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Neurodegenerative Diseases, Parkinson Disease, Parkinson Disease Psychosis
Interventions
Pimavanserin
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
50 Years to 85 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Parkinson's Disease
Interventions
cannabidiol
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Dementia-related Psychosis
Interventions
Placebo, Pimavanserin 34 mg, Pimavanserin 20 mg
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
27
States / cities
Costa Mesa, California • Fullerton, California • Aventura, Florida + 22 more
Conditions
Parkinson Disease Psychosis
Interventions
Iloperidone
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
65 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
St. Petersburg, Florida
Conditions
Parkinson's Disease, Psychoses
Interventions
aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Albany, New York
Conditions
Parkinson's Disease Psychosis, Dementia With Lewy Bodies
Interventions
Pimavanserin, Quetiapine
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Not listed
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
San Antonio, Texas
Conditions
Parkinson's Disease
Interventions
EMD 128130, IV Levodopa
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Completed No phase listed Observational Accepts healthy volunteers

Psychiatric and Cognitive Manifestations of Parkinson's Disease

NCT00360633
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2019
U.S. locations
1
States / cities
New York, New York
Conditions
Hallucinations, Psychoses, Parkinson's Disease
Interventions
ACP-103
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
0 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
13
States / cities
Fountain Valley, California • Sunnyvale, California • Danbury, Connecticut + 10 more
Conditions
Dementia, Parkinson Disease
Interventions
Quetiapine
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
21
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 18 more
Recruiting Phase 4 Interventional Accepts healthy volunteers

Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis

NCT04373317
Conditions
Parkinson's Disease Psychosis
Interventions
Pimavanserin, Quetiapine
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
358 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
24
States / cities
Tucson, Arizona • Loma Linda, California • Palo Alto, California + 20 more
Recruiting Not applicable Interventional Accepts healthy volunteers

Cerebellar Stimulation and Cognitive Control

NCT03217110
Conditions
Schizophrenia, Autism Spectrum Disorder, Bipolar Disorder, Depression, Parkinson Disease
Interventions
Repetitive Transcranial Magnetic Stimulation (rTMS), Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
Device
Lead sponsor
Krystal Parker, PhD
Other
Eligibility
18 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2028
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Parkinson Disease
Interventions
Cannabidiol, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 85 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Parkinson Disease
Interventions
Pimavanserin
Drug
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
40 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Brooklyn, New York
Completed No phase listed Observational Accepts healthy volunteers

PET Scanning in Parkinson s Disease

NCT00024622
Conditions
Schizophrenia, Parkinson's Disease
Interventions
18F-Fluoro-L-dopa, O-15 Water
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 90 Years
Enrollment
502 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Parkinson Disease Psychosis
Interventions
Real-world, non-interventional
Other
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
764 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
69
States / cities
Cullman, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 62 more
Conditions
Parkinson's Disease Psychosis
Interventions
Pimavanserin tartrate (ACP-103), Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
40 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
36
States / cities
Gilbert, Arizona • Phoenix, Arizona • Berkeley, California + 33 more
Conditions
Parkinson Disease Psychosis
Interventions
Pimavanserin
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
40 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
18
States / cities
Scottsdale, Arizona • Fullerton, California • Miami, Florida + 15 more